MOv19-BBz
CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Principal Investigator |
Phase | Penn Study Number | Clinicaltrials.gov ID |
|---|---|---|---|
| Payal D Shah MD | 1 | UPCC | NCT03585764 |
Purpose
This is a Phase I study evaluating the safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells in 4 cohorts with or without cyclophosphamide + fludarabine in a 3+3 dose escalation design.
Check Eligibility for this Trial
To inquire about participating in this study, please contact CareBox, Penn Medicine's Clinical trial information Service